[Intervention Factors and Outcome Analysis of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia]
Related Experiment Video
Updated: Sep 29, 2026
Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice
Published on: December 8, 2023
Yu-Jie Ji1, Zi-Yan Jin1, Xiao Ma1,2
1Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Jiangsu Key Laboratory of Hematologic Diseases, Suzhou 215006, Jiangsu Province, China.
Objective:
To analyze the outcomes and associated intervention factors in elderly patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Methods:
A retrospective analysis was performed on 67 AML patients aged≥60 years who received allo-HSCT in the First Affiliated Hospital of Soochow University and Soochow Hopes Hematonosis Hospital from June 2012 to September 2024. Based on HCT-CI score, the patients were divided into 0-1 group (36 cases), 2-3 group (20 cases) and≥4 group (11 cases), and the differences in survival, relapse, transplant-related mortality (TRM), disease-free survival (DFS), graft-versus-host disease (GVHD) and GVHD-free, relapse-free survival (GRFS) among the 3 groups were compared.
Results:
Among the 67 patients, the 1-year survival rate was 68.66%, 1-year relapse rate was 19.40%, 1-year TRM was 14.93%, and 1-year DFS rate was 67.16%. There were no significant differences in survival, relapse, TRM, DFS, GVHD and GRFS among HCT-CI 0-1, 2-3 and≥4 groups.
Conclusion:
Allo-HSCT has good outcomes for AML patients aged≥60 years. There was no significant correlation between HCT-CI score and survival outcome.
